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SUMMARY
Domino liver transplantation using FAP livers
(DLTx/FAP) has become a worldwide strategy that is con-
tributing significantly to the increase in liver grafts
offered in Portugal. The safety of the procedure both in
the FAP donors and in the recipients is emphasized in the
series of 64 DLTx/FAP that has already been perfonned
in the Hospital of the University of Coimbra (HUC). The
occurrence of amyloidosis in the long-term survivors
after DLTx/FAP is a serious possibility, although after 6
and 7 years post-transplant no symptoms have been
reported by any of the patients. Indeed, amyloid deposits,
although small, have been found in the skin and nerve
biopsies of the first domino recipients (HUC unpublished
data). Hopes that the disease will have a slow course in
non-genetically affected patients still awaits the proof of
time. Thus, DLTx/FAP should be considered an experi-
mental procedure, although there is good reason to expect
that the amyloidosis in the DLTx/FAP recipients will have
a longer time course than in the genetically affected
donors. The ethical implications of all these facts and
expectations are discussed. A case by case approach is
recommended. In such an approach, individual prognosis,
urgency, graft shortage and the will of very well-informed
patients or their legal representatives are determinants
for judicious decisions when considering DLTx/FAP in
patients under 50 years of age.
Introduction
Orthotopic liver transplantation (OLTx) for familialamyloidotic polyneuropathy (FAP) patients wasfirst proposed by Holmgren et al, in 1990'. This
was a major hope for changing the prognosis of the fatal
course of this hereditary disease. Indeed, no other therapy
has yet shown any promise of halting the inexorable evo-
lution to death of FAP patients, whatever the mutation
involved^. OLTx with non-FAP liver grafts suppresses the
major source of the abnormal protein (the FAP liver itself)
which is at the center of the amyloidogenie process that
ultimately leads to the polyneuropathy.
The main pools of FAP are found in Portugal, Sweden
and Japan. In these communities, the ATTR VaBOMet
variant is prevalent. In Portugal, where the disease was
first unveiled and characterized by Corino de Andrade in
the 1960s3, the Val30Met TTR gene mutation is almost
exclusive. Although the disease is systemic, the liver
functions are not usually affected. To our knowledge, not
a single case of liver failure due to FAP has ever been
described in Portugal.
In 1995, we began using the livers removed from
FAP patients (while undergoing OLTx) as grafts for some
selected non-FAP patients'*. Originally, we named this
procedure sequential liver transplantation but it became
most often reported as domino liver transplantation
(DLTx/FAP).
In the Transplant Unit of the Hospital of the
University of Coimbra (UPT/HUC), a total of 62 patients
have undergone this procedure. An overview of this series
is presented below. Initial hopes and present realities are
discussed.
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Rationale and ethical problems
These grafts resume the production of the abnormal
protein as soon as they become revaseularized. The main
rationale basis for this innovative procedure is that, in
genetically affected patients, there is no clinical expres-
sion of the disease under the age of 20 years^ (usually
more than 25 in the Portuguese population), the disease is
not clinically relevant before 30 and rarely fatal under 35.
Thus, it is reasonable to expeet that, in non-genetically
affected patients who receive FAP livers, the disease, if it
appears, would follow the same or an even slower eourse
than in the FAP patients. So, if a non-FAP patient receives
a FAP liver graft at 50 and develops FAP, he would not die
from this disease before 85 years of age. As the offer of
cadaveric grafts always falls short of the needs, using FAP
livers in patients included on long waiting lists could sig-
nificantly shorten the waiting time for OLTx, both in FAP
and non-FAP patients.
FAP grafts offer the advantages of living grafts —
absence of ischemie injury related to the death of cadav-
eric donors, short isehemic times, programmed selection
of the pair donor—reeipient and, as a result, enhanced
chances of immediate better function. Another unique
advantage of these grafts is that they are the only avail-
able whole grafts in the living set, although, obviously,
they may also be used as reduced or split grafts^-io.
Two main ethical principles must preside in the
DLTx/FAP procedure: it should not add any risk to the
FAP donors and a detailed informed consent of the
patients or of their legal representatives must be obtained.
Information on the experimental character of the proee-
dure and on the possibility of the appearance of poly-
neuropathy in the recipients is mandatory.
Material and methods
piggy-back technique was used (with two exceptions) in
patients with tumors located far from the vena cava and in
patients with benign pathology. An external veno-venous
by-pass was always used during the FAP patient s hepat-
ectomy and in the recipient when the retrohepatic vena
cava was not preserved (mainly tumors). Thirteen
DLTx/FAP recipients, unanimously eonsidered to have
extremely bad prognoses, were under 45 years of age
(Tables 3 and 4). In three cases, combined DLTx/FAP
with split allowed transplantation in 3 recipients starting
with only one cadaver graft.
Results
Survival curves for the domino recipients and the
grafts are shown in Figure 1.
Three patients required retransplantation (4.7%): two
of these patients had two consecutive DLTx/FAP: a 53-
year-old aleoholic and HCV cirrhotie woman who devel-
oped and died of sepsis, and a 55-year-old HVB cirrhotic
man who developed fulminant liver failure, 1 month after
the first DLTx/FAP; he is very well 4 years later. The third
patient lost his DLTx/FAP graft because of hepatic artery
thrombosis (9th post-operative day of DLTx/FAP); for
Table 2. Indications for DLTx/FAP (HUC series)
Malignant pathology 26
Hepatocellular carcinoma 18
Neuroendocrine tumor 5
Metastasis carcinoma colon 1
Others 2
Benign pathology 36
Cirrhosis 28
Alcoholic 14
Viral 11
Other cirrhosis 3
Acute liver failure 4
Chronic rejection 1
Others 3
Sixty-two patients aged 28—63 years received 64
DLTx/FAP. General demographics are presented in Table
1, and the indications for transplant in Table 2. The
implantations followed the classic technique (non-
preservation of the recipients vena cava) in patients with
malignancies close to the vena cava (1 cm or less). A
Table 1. Characteristics of DLTx/FAP patients (HUC
series, Oct. 1995-Dec. 2002)
Recipients
Male
Age (years)
62
48
28-63 (med. 50)
DLTx
Female
64
14
IOO -
80 •
' '» 6 0 •
4 0 •
20 -
1 2
Surv
3
ival (years)
Overall patients
Catieer patietit.s
Non-cattcer patients
4 5
FIGURE 1: Actuarial survival curves for DLTx/FAP recipi-
ents.
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Table 3.
Age
Exceptional indications
Pathology
(> 40 years < 45 years - 6 recipients)
Alive Dead
44 Hepatocellular carcinoma - portal thrombosis 37 months
45 Hepatoceilular carcinoma (a1-antitrypsine deficiency + pulmonary fibrosis
45 Hepatocellular carcinoma (alchoholic cirrhosis) 10 months
45 Neuroendocrine tumor (kidney Tx) 31 months
Alcoholic cirrhosis (doubtful compliance) 10 months
12 months
44
Table 4.
Age
Wilson cirrhosis (coma, acute respiratory distress
Exceptional indications (< 40 years - 7 recipients)
Pathology
syndrome)
Alive Dead
Brain death
33
28
33
29
35
34
39
Hepatoceilular carcinoma
Hemolysis, elevated liver enzymes,
low platelet syndrome (HELLP) - 3rd Tx
Acute liver failure - 3rd Tx
1 year - recurrence
2 months - multiple organ failure
Chronic rejection. Death
at 39 months. Refused ReTx
4 months - MetHemangiosarcoma
Crypt C (Jehovah's Witness) 2 years - very well
Acute liver failure - primary non-function - 2nd Tx 10 months - very well
Acute liver failure - primary non-function - 2nd Tx 35 days - sepsis
logistic reasons, he was retransplanted with a cadaver
graft and is well at 4 years post-transplantation. The out-
comes of the 13 recipients aged less than 45 years, whom
we considered to have exceptional indications, are
included in Tables 3 and 4.
Discussion
Organ shortage is the main cause of long waiting
times for OLTx of many patients who, meanwhile, see
their clinical condition worsening or even die. Since our
original report of the first DLTx/FAP'', the procedure has
gained wide acceptance". Early on in our experience, we
were confronted with clinical situations that prompted
the change of the original indications we had established
for advising the procedure: malignant pathology in recip-
ients above 50 years.
The absence of any FAP symptoms or electromyo-
graphic changes, along with the slow deposition of
amyloid in the skin or in the sural nerves of the patients
who received DLTx/FAP 6 to 7 years ago, underline the
expectation that amyloidosis in the recipients of FAP
livers would not be a problem for the great majority of
these patients. The risks of recurrence of the original
disease (malignancies, viral hepatitis, alcoholic recidi-
vism, etc.) and the negative impact of the immunosup-
pression, probably represent greater risks than the risks of
dying of FAP, at least in patients over 40 years. The
advantages of using the livers of FAP patients seem indis-
putable. They are further emphasized in countries with
many FAP patients awaiting OLTx as their only hope of
stopping the course of the disease. The opportunities for
OLTx of FAP patients on long waiting lists which include
many other non-FAP liver patients became more and
more a problem in Portugal. In the UPT/HUC series,
DLTx has been very well accepted, both by FAP and non-
FAP patients, who realized the mutual benefits of that
strategy. This has meant that most of the FAP patients
transplanted in our Unit during recent years were domino
donors who, otherwise, would have been transplanted
later or who would not have been transplanted at all.
Since the beginning of its practice, DLTx/FAP has con-
tributed 16% of the total grafts used in our series of 500
liver transplants. Improvements in logistics and coopera-
tion between centers may allow an increase of this contri-
bution to 25—30%.
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Establishing a guide to the lower age limit for
DLTx/FAP candidates is a relevant but not an easy issue
to solve. Some exceptional cases must be approached on
an individual basis, perhaps with the contribution of
ethical committees. Deciding factors range from the will-
ingness of the candidate to be transplanted as early as pos-
sible to the urgency of the situation. When dealing with
malignancies or viral and alcoholic cirrhosis, we propose
DLTx/FAP strategy for patients over 40 years. Some very
special situations may justify or even impose resorting to
DLTx/FAP; this is the case in young patients with very
bad prognoses at short- or mid-term in whom a second or
third non-FAP graft would not be provided. Our experi-
ence, shown in Tables 2 and 3, seems quite explicit —
some cadaveric grafts would have been wasted if they had
not been used in FAP patients, but a few patients would
not have been saved if it were not for the possibility of
DLTx/FAP. In the group of patients between 40 and 45
years of age (Table 3) the prognosis of the four survivors
is rather uncertain (3 cancers). The mortality in the group
under 40 years (Table 4) shows clearly that they were
patients with extremely bad prognoses. The indications
for DLTx/FAP in the only two survivors were, in one
patient, a deliberate option to assure the best initial func-
tion in a very difficult transplantation in a Jehovah s
Witness'^ with no blood transfusion allowed (dismissed
from the hospital — day 11) and, in another patient, a
primary non-function (PNF) after a failed first cadaveric
transplant (acute liver failure, unknown etiology); in this
case and at the time the super-urgent call was issued, the
only available graft was a FAP patient s liver. Extreme
organ shortage may justify DLTx/FAP in patients even
younger than those we have transplanted'^.
The survival curves in this series are almost exclu-
sively related to crucial factors of the recipient pathology
(severity of the disease, eomorbidity, general condition,
etc.). Indeed, the series includes a high percentage of very
high-risk or desperate cases. Only one graft loss was
ascribable to technical failure (hepatic artery thrombosis).
No cases of PNF occurred in this series. The low retrans-
plantation rate (4.7%) further emphasizes the excellent
quality ofthese grafts. This was the main reason for pre-
ferring DLTx/FAP in the very difficult case of transplan-
tation in a young Jehovah s Witness, with prohibition of
using blood or blood derivatives'2.
Conclusions
DLTx/FAP is a strategy definitely established as a
safe procedure both for FAP donors and for non-FAP
recipients. Initial very good function of the graft and very
low probability of PNF are the rule. Morbidity and sur-
vival rates are mainly related to the recipient s pathology.
The development of FAP after DLTx/FAP is to be
expected in some long-living recipients. Thus, clinical
indications (mainly taking into account some crucial
factors such as age, urgency and prognosis) imply diffi-
cult ethical considerations derived from the possibility of
FAP development in the recipients. A detailed informed
consent and team discussion are key elements to judicious
decisions before indicating this procedure, which must
still be considered experimental.
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